Nanoparticles as a tool to deliver drugs to the retina and brain: an update

You, Qing; Sabel, Bernhard A.

doi:10.4103/1673-5374.290886

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The research on pharmacologic and genetic administration of retinoprotective proteins has had unprecedented success in generating different treatments toward the recovery of vision loss. Regarding the pharmacologic approach using exogenously prepared proteins and peptides as cargo molecules, a variety of neuron-targeted nanoparticles are avail-able to deliver the cargo and to enhance neuronal protection [64]. Significant progress includes the understanding of the uptake mechanism and the physicochemical properties of nanoparticles and microparticles to encapsulate proteins [64].…”

Section: Future Directions For Protein Delivery Systems In Ocular Researchmentioning

confidence: 99%

“…Regarding the pharmacologic approach using exogenously prepared proteins and peptides as cargo molecules, a variety of neuron-targeted nanoparticles are avail-able to deliver the cargo and to enhance neuronal protection [64]. Significant progress includes the understanding of the uptake mechanism and the physicochemical properties of nanoparticles and microparticles to encapsulate proteins [64]. The use of novel delivery methodologies, such as microneedles and intravitreal implants that allow the gradual intraocular release of proteins and carriers that are specifically designed for ocular research [65] are increasing the efficacy of the pharmacologic administration of retinoprotective proteins to target retinopathies.…”

Section: Future Directions For Protein Delivery Systems In Ocular Researchmentioning

confidence: 99%

See 1 more Smart Citation

Delivery Systems of Retinoprotective Proteins in the Retina

Rebustini¹,

Bernardo-Colón²,

Nalvarte³

et al. 2021

IJMS

View full text Add to dashboard Cite

Retinoprotective proteins play important roles for retinal tissue integrity. They can directly affect the function and the survival of photoreceptors, and/or indirectly target the retinal pigment epithelium (RPE) and endothelial cells that support these tissues. Retinoprotective proteins are used in basic, translational and in clinical studies to prevent and treat human retinal degenerative disorders. In this review, we provide an overview of proteins that protect the retina and focus on pigment epithelium-derived factor (PEDF), and its effects on photoreceptors, RPE cells, and endothelial cells. We also discuss delivery systems such as pharmacologic and genetic administration of proteins to achieve photoreceptor survival and retinal tissue integrity.

show abstract

Section: Future Directions For Protein Delivery Systems In Ocular Researchmentioning

confidence: 99%

Section: Future Directions For Protein Delivery Systems In Ocular Researchmentioning

confidence: 99%

Delivery Systems of Retinoprotective Proteins in the Retina

Rebustini¹,

Bernardo-Colón²,

Nalvarte³

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

Nanotechnology in the diagnosis of ocular diseases, drug delivery, and therapy

Mishra

Talegaonkar

Rai

et al. 2023

Nanotechnology in Ophthalmology

View full text Add to dashboard Cite

Nanomedicine strategies for central nervous system (CNS) diseases

Nagri,

Rice,

Chen

2023

Front. Biomater. Sci.

View full text Add to dashboard Cite

The blood-brain barrier (BBB) is a crucial part of brain anatomy as it is a specialized, protective barrier that ensures proper nutrient transport to the brain, ultimately leading to regulating proper brain function. However, it presents a major challenge in delivering pharmaceuticals to treat central nervous system (CNS) diseases due to this selectivity. A variety of different vehicles have been designed to deliver drugs across this barrier to treat neurodegenerative diseases, greatly impacting the patient’s quality of life. The two main types of vehicles used to cross the BBB are polymers and liposomes, which both encapsulate pharmaceuticals to allow them to transcytose the cells of the BBB. For Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and glioblastoma brain cancer, there are a variety of different nanoparticle treatments in development that increase the bioavailability and targeting ability of existing drugs or new drug targets to decrease symptoms of these diseases. Through these systems, nanomedicine offers a new way to target specific tissues, especially for the CNS, and treat diseases without the systemic toxicity that often comes with medications used currently.

show abstract

Nanoparticles as a tool to deliver drugs to the retina and brain: an update

Cited by 3 publications

References 10 publications

Delivery Systems of Retinoprotective Proteins in the Retina

Delivery Systems of Retinoprotective Proteins in the Retina

Nanotechnology in the diagnosis of ocular diseases, drug delivery, and therapy

Nanomedicine strategies for central nervous system (CNS) diseases

Contact Info

Product

Resources

About